Abstract
BackgroundAutologous CAR T cell therapies have revolutionized the treatment of hematologic malignancies but have inherent disadvantages that hinder widespread access, including complex logistics and manufacturing limitations. These challenges may be...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
